Key result
CCM therapy improves NYHA class and reduces NT-proBNP in a severe heart failure case.
Why the study?
Cardiac contractility modulation therapy appears to act at cellular and molecular levels altered in heart failure, but clinical experience remains limited.
Population
73-year-old man with severe left ventricular dysfunction and recurrent acute decompensated heart failure
Comparison
CCM therapy active versus inactive (battery depletion) periods
Design
Case report
Authors
Loading...
Case of CCM in post-MI HF with ICD supports further exploration; leaves open efficacy and safety in controlled trials.
Case Report (n=1)
Cardiac contractility modulation therapy provided sustained clinical improvement and reduced hospitalizations in a patient with severe left ventricular dysfunction.
Dadamo et al. (2026) conducted a case report in Heart failure (n=1). Cardiac contractility modulation (CCM) therapy was evaluated. Cardiac contractility modulation therapy improved clinical status by at least one NYHA functional class and reduced NT-proBNP levels in a 73-year-old man with severe heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: